BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 15258910)

  • 21. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
    Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A
    Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation.
    Hurlin PJ; Quéva C; Koskinen PJ; Steingrímsson E; Ayer DE; Copeland NG; Jenkins NA; Eisenman RN
    EMBO J; 1995 Nov; 14(22):5646-59. PubMed ID: 8521822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo.
    James L; Eisenman RN
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10429-34. PubMed ID: 12149476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromatin dynamics at the hTERT promoter during transcriptional activation and repression by c-Myc and Mnt in Xenopus leavis oocytes.
    Wahlström T; Belikov S; Arsenian Henriksson M
    Exp Cell Res; 2013 Dec; 319(20):3160-9. PubMed ID: 23860446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the Max-binding protein MNT in human medulloblastomas.
    Sommer A; Waha A; Tonn J; Sörensen N; Hurlin PJ; Eisenman RN; Lüscher B; Pietsch T
    Int J Cancer; 1999 Sep; 82(6):810-6. PubMed ID: 10446446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Myc/Max/Mad network and the transcriptional control of cell behavior.
    Grandori C; Cowley SM; James LP; Eisenman RN
    Annu Rev Cell Dev Biol; 2000; 16():653-99. PubMed ID: 11031250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
    Chen Y; Tsai YH; Tseng SH
    Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
    Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
    Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
    Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
    Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positive auto-regulation of MYCN in human neuroblastoma.
    Suenaga Y; Kaneko Y; Matsumoto D; Hossain MS; Ozaki T; Nakagawara A
    Biochem Biophys Res Commun; 2009 Dec; 390(1):21-6. PubMed ID: 19766596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.
    Henriksen JR; Haug BH; Buechner J; Tømte E; Løkke C; Flaegstad T; Einvik C
    BMC Dev Biol; 2011 Jan; 11():1. PubMed ID: 21194500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYCN-mediated overexpression of mitotic spindle regulatory genes and loss of p53-p21 function jointly support the survival of tetraploid neuroblastoma cells.
    Gogolin S; Batra R; Harder N; Ehemann V; Paffhausen T; Diessl N; Sagulenko V; Benner A; Gade S; Nolte I; Rohr K; König R; Westermann F
    Cancer Lett; 2013 Apr; 331(1):35-45. PubMed ID: 23186832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif.
    Hurlin PJ; Steingrìmsson E; Copeland NG; Jenkins NA; Eisenman RN
    EMBO J; 1999 Dec; 18(24):7019-28. PubMed ID: 10601024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
    Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
    Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation.
    Ayer DE; Eisenman RN
    Genes Dev; 1993 Nov; 7(11):2110-9. PubMed ID: 8224841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis.
    Hurlin PJ; Foley KP; Ayer DE; Eisenman RN; Hanahan D; Arbeit JM
    Oncogene; 1995 Dec; 11(12):2487-501. PubMed ID: 8545105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mycN/max protein complex in neuroblastoma. Short review.
    Wenzel A; Schwab M
    Eur J Cancer; 1995; 31A(4):516-9. PubMed ID: 7576956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
    Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
    Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.